Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Yvonne Chu

Ophthalmology Houston, TX Medical Doctor

NPI 1033108410 CMS profile 47215

6550 Fannin St, Suite 1501, Houston, TX 77030

Open in the dashboard

General payments

$14,519

154 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Yvonne Chu of Houston, TX is reported in the CMS Open Payments database as having received $14,519 across 154 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,862 16
2024 General $1,487 17
2023 General $1,795 17
2022 General $1,846 20
2021 General $1,979 26
2020 General $1,136 13
2019 General $4,414 45

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Yvonne Chu
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Yvonne Chu were reported at $1,862. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Yvonne Chu Ophthalmology median Middle half National median
2019 $4,414 $258 $104–$655 $163
2020 $1,136 $126 $45–$321 $114
2021 $1,979 $205 $76–$534 $132
2022 $1,846 $266 $100–$678 $149
2023 $1,795 $308 $117–$745 $160
2024 $1,487 $340 $127–$846 $164
2025 $1,862 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. New World Medical,Inc. $3,371 30 payments
  2. Alcon Vision LLC $2,113 26 payments
  3. Glaukos Corporation $1,753 12 payments
  4. Allergan Inc. $1,654 20 payments
  5. AbbVie, Inc. $1,356 17 payments
  6. Optos, Inc. $827 5 payments
  7. Aerie Pharmaceuticals, Inc. $822 8 payments
  8. Ivantis, Inc $771 7 payments
  9. Bausch & Lomb, a division of Bausch Health US, LLC $705 14 payments
  10. Iridex Corporation $344 3 payments
  11. Other $803 12 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,842 150 payments
  2. Entertainment $677 4 payments
Products named General payments · program years 2019–2025
  1. Ahmed Glaucoma Valve $2,804 25 payments
  2. Kahook Dual Blade $2,804 25 payments
  3. HYDRUS Microstent $1,126 14 payments
  4. Clearpath $1,039 7 payments
  5. Streamline $1,039 7 payments
  6. XEN GLAUCOMA TREATMENT SYSTEM $996 10 payments
  7. Via360 $833 5 payments
  8. P200DTx $827 5 payments
  9. P200TxE $827 5 payments
  10. P200T $827 5 payments
  11. Other $10,987 134 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$5,169

Medicare's payments for the services billed

Medicare patients

31

Average age 71

Services billed

43

15 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 68%
Chronic kidney disease 42%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MIEBO
  • Bausch & Lomb Americas Inc. $43
$43 — —
VYZULTA
  • Bausch & Lomb Americas Inc. $43
$43 — —
XIIDRA
  • Bausch & Lomb Americas Inc. $43
$43 — —
DURYSTA
  • AbbVie, Inc. $17
$17 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

154 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record